Find the Best New Indication, Fast, with BioMAP® Drug Repositioning Services
Prioritizing alternative or secondary indications suitable for an approved drug or late stage candidate is a challenge that requires evidence-based guidance prior to the start of expensive and lengthy
in vivo studies. The BioMAP Phenotypic Profiling Platform utilizes physiologically and clinically relevant human primary cell-based disease models as a powerful tool that can identify novel efficacy and predict disease impact outside the primary or approved indications.
By adding BioMAP to your drug repurposing program you will:
- Give new life to drugs and candidates by quickly identifying new indications across a broad range of tissue and disease states
- Find new markets faster by using a platform that integrates hundreds of assays across dozens of disease states
- Get direct consultation with BioMAP scientists for personalized data analysis and interpretation to guide candidate advancement
Request a Quote
BioMAP Accelerates Drug Repositioning Programs
